Home > Resources > Company Profiles > Eli Lilly & Company > People

Eli Lilly & Company (LLY)

Your Name

Your Email Address *
Send a copy to me

Recipient's Email Address *

Separate multiple email addresses (max 20) with commas.

Subject *

Message

0/1500

Email Confirmation

Dr. John C. Lechleiter, Ph.D. , President/COO/Director/CEO

www.lilly.com

Industry: Healthcare

OPEN

LAST

PREV CLOSE

CHANGE

VOLUME

Overview

News

People

Financials

Overview

The Company discovers, develops, manufactures and sells products in one segment of pharmaceutical products.

Press Releases

Schaeffer's Early Edge: eBay, Eli Lilly, and Yahoo! Nov-28-2008, 09:40AM EST
Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain Nov-28-2008, 08:00AM EST
TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel Nov-25-2008, 08:30AM EST
Fitch Downgrades Eli Lilly & Co.'s IDR to 'A+'; Outlook Stable Nov-24-2008, 02:08PM EST
Lilly Completes Acquisition of ImClone Systems Nov-24-2008, 09:28AM EST

News From Around the Web

News

Final Glance: Pharmaceuticals companies (Businessweek)

Dec 04 2008
Drug Deals Require Cash (Motley Fool)

Dec 04 2008
Pharmaceuticals companies shares down at noon (Canadian Business Online)

Dec 04 2008
Pharmaceuticals companies shares down at 10 a.m. (Canadian Business Online)

Dec 04 2008
Eli Lilly files suit against two Indian cos. (The Hindu, India)

Dec 04 2008
Pharmaceuticals companies shares up at the close of trading (Canadian Business Online)

Dec 03 2008
Early Glance: Pharmaceuticals companies (Boston Globe)

Dec 03 2008
Drug firms fight with foreign cos over patents (Economic Times, India)

Dec 03 2008
Eli Lilly files suit against Lupin, Aurobindo (Rediff)

Dec 03 2008

Blogs

Is Merck A Drug Bellwether? (CNBC: Pharmas Market with Mike Huckman)

Dec 04 2008
Drugmakers in M&A Frenzy – J&J gets a boob job and more (Hoover's: Bizmology)

Dec 03 2008
Sam Waksal: "Moving On Up" To The East Side (CNBC: Pharmas Market with Mike Huckman)

Dec 02 2008
Predictions: 9 For '09 In Pharma (CNBC: Pharmas Market with Mike Huckman)

Dec 01 2008

Employees

Number of Employees: 40,600

Revenue per Employee: $426,246

Top Executives

Robert A. Armitage, Senior VP/General Counsel

Bryce D. Carmine, Executive VP, Divisional

Dr. Steven M. Paul, M.D., Executive VP, Divisional

Alex M. Azar, II, Senior VP, Divisional

Derica W. Rice, CFO/Senior VP

Arnold C. Hanish, Chief Accounting Officer

Anthony J. Murphy, Ph.D., Divisional Senior VP

Gino Santini, Divisional Senior VP

Frank M. Deane, Ph.D., President, Divisional

Scott A. Canute, Divisional President

Deirdre P. Connelly, Divisional President

Board of Directors

Michael L. Eskew, Director

Dr. Franklyn G. Prendergast, M.D., Ph.D., Director

Dr.Karen N. Horn, Ph.D., Director

Douglas R. Oberhelman, Director

Dr.Alfred G. Gilman, M.D., Ph.D., Director

Sidney Taurel, Chairman of the Board/Director

Kathi P. Seifert, Director

Ellen R. Marram, Director

J. Erik Fyrwald, Director

Dr.Martin S. Feldstein, Ph.D., Director

J. Michael Cook, Director

Sir Winfried F. W. Bischoff, Director

Financials

Quarterly

Annual

Income Statement	10/2008	07/2008	04/2008	01/2008
Sales	1.16 Bil.	NA	1.11 Bil.	1.27 Bil.
Gross Operating Profit	4.05 Bil.	1.2 Bil.	3.7 Bil.	3.92 Bil.
Operating Income before D & A (EBITDA)	1.45 Bil.	1.2 Bil.	1.27 Bil.	1.21 Bil.
Total Income Before Interest Expenses (EBIT)	-214 Mil.	1.2 Bil.	1.06 Bil.	1.14 Bil.
Total Net Income	-465.6 Mil.	80.26 Mil.	1.06 Bil.	854.4 Mil.
Basic EPS, Total	-0.43	0.48	0.97	0.78
Diluted EPS, Total	-0.43	0.46	0.97	0.78

BALANCE STATEMENT	10/2008	07/2008	04/2008	01/2008
Cash and Equivalents	NA	NA	NA	NA
Total Assets	NA	NA	NA	NA
Total Liabilities	NA	NA	NA	NA
Total Capitalization	NA	NA	NA	NA

Cash Flow	10/2008	07/2008	04/2008	01/2008
Net Cash From Continuing Operations	NA	NA	NA	NA
Net Cash From Investing Activities	NA	NA	NA	NA
Net Cash From Financing Activities	NA	NA	NA	NA
Net Change in Cash & Cash Equivalents	NA	NA	NA	NA

Income Statement	2008	2007	2006	2005
Sales	4.25 Bil.	2.74 Bil.	2.75 Bil.	2.63 Bil.
Gross Operating Profit	14.38 Bil.	12.95 Bil.	11.9 Bil.	11.23 Bil.
Operating Income before D & A (EBITDA)	4.8 Bil.	4.93 Bil.	4.38 Bil.	4.26 Bil.
Total Income Before Interest Expenses (EBIT)	3.89 Bil.	3.66 Bil.	2.82 Bil.	2.99 Bil.
Total Net Income	295.3 Bil.	2.66 Bil.	1.98 Bil.	1.81 Bil.
Basic EPS, Total	2.71	2.45	1.82	1.67
Diluted EPS, Total	2.71	2.45	1.81	1.66

BALANCE STATEMENT	2008	2007	2006	2005
Cash and Equivalents	NA	3.11 Bil.	3.01 Bil.	5.37 Bil.
Total Assets	NA	9.69 Bil.	10.8 Bil.	12.84 Bil.
Total Liabilities	NA	5.09 Bil.	5.72 Bil.	7.59 Bil.
Total Capitalization	NA	14.48 Bil.	16.56 Bil.	15.41 Bil.

Cash Flow	2008	2007	2006	2005
Net Cash From Continuing Operations	NA	3.98 Bil.	1.91 Bil.	2.87 Bil.
Net Cash From Investing Activities	NA	608.4 Mil.	-2.22 Bil.	-684.8 Mil.
Net Cash From Financing Activities	NA	-4.58 Bil.	-1.88 Bil.	203.7 Mil.
Net Change in Cash & Cash Equivalents	NA	102.6 Mil.	-2.36 Bil.	2.61 Bil.

Eli Lilly & Company (LLY)

Company Information

Overview

Employees

Top Executives

Board of Directors

Financials

Company Profile Change Request